- Home
- TOPS vs GDTC Comparison
TOPS vs GDTC Comparison
Compare TOPS & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- GDTC
- Stock Information
- Founded
- TOPS 2000
- GDTC 2018
- Country
- TOPS Greece
- GDTC Singapore
- Employees
- TOPS N/A
- GDTC N/A
- Industry
- TOPS Marine Transportation
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- GDTC Health Care
- Exchange
- TOPS Nasdaq
- GDTC Nasdaq
- Market Cap
- TOPS 27.2M
- GDTC 21.5M
- IPO Year
- TOPS 2004
- GDTC 2023
- Fundamental
- Price
- TOPS $5.95
- GDTC $1.89
- Analyst Decision
- TOPS
- GDTC Buy
- Analyst Count
- TOPS 0
- GDTC 1
- Target Price
- TOPS N/A
- GDTC $5.00
- AVG Volume (30 Days)
- TOPS 18.2K
- GDTC 18.1K
- Earning Date
- TOPS 08-08-2025
- GDTC 01-01-0001
- Dividend Yield
- TOPS N/A
- GDTC N/A
- EPS Growth
- TOPS N/A
- GDTC N/A
- EPS
- TOPS 1.09
- GDTC N/A
- Revenue
- TOPS $86,127,000.00
- GDTC $368,838.00
- Revenue This Year
- TOPS $9.90
- GDTC $5.37
- Revenue Next Year
- TOPS N/A
- GDTC N/A
- P/E Ratio
- TOPS $5.58
- GDTC N/A
- Revenue Growth
- TOPS 3.83
- GDTC N/A
- 52 Week Low
- TOPS $5.00
- GDTC $1.20
- 52 Week High
- TOPS $11.47
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- TOPS 46.80
- GDTC 37.08
- Support Level
- TOPS $5.91
- GDTC $1.85
- Resistance Level
- TOPS $6.36
- GDTC $1.95
- Average True Range (ATR)
- TOPS 0.36
- GDTC 0.10
- MACD
- TOPS 0.02
- GDTC -0.02
- Stochastic Oscillator
- TOPS 18.92
- GDTC 28.00
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.